QantX
VC Fund
Exeter, United Kingdom
QantX is a VC fund in Exeter focused on Health Care and Medical. High impact innovation investment
- Total investments:
- 27
- Last investment:
- Lead investor:
- 22%
Last updated:
For AI agents: llms.txt
Industries QantX invests in
Stages QantX invests in
Countries QantX invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Seed
- $471k–$6.5M
- Angel
- $382k–$1.3M
- Pre-Seed
- $764k–$1.1M
Investment Focus
Industry
- Health Care 6 (22%)
- Medical 4 (15%)
- Biotechnology 3 (11%)
- Pharmaceutical 3 (11%)
- SaaS 2 (7%)
Stage
- Seed 11 (41%)
- Angel 3 (11%)
- Pre-Seed 3 (11%)
- Funding Round 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Richard Haycock
CEO
|
CEO | Total investments: 9 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Revolver Therapeutics
|
Revolver Therapeutics develops peptide therapeutics that target transcription factors to create new routes to cancer treatment. The company uses a proprietary peptide discovery and screening platform, including its Transcription Block Survival technology, to identify functional peptide inhibitors in live cell systems. This platform enables rapidscreening of large peptide libraries and enrichment of molecules that functionally block or modulate transcription factor activity. Revolver Therapeutics focuses on translating its peptide-based transcription factor screening technology into therapeutic candidates for oncology. Its work is based on research spun out from the University of Bath and is aimed at generating next-generation peptide drugs for difficult-to-treat cancers. | $764K / Pre-Seed / Jul 03, 2026 | |
Neuronostics
|
Neuronostics Ltd is a newly established University of Exeter (UK) spin-out, focussed on the development and commercialisation of a novel and potentially revolutionary seizure susceptibility assessment technology called #BioEP. | $4M / Seed / Jun 30, 2026 | |
iFast Diagnostics
|
iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance. | $3.9M / Seed / May 27, 2026 | |
LabCycle
|
LabCycle is the world's first company to recycle hazardous plastic waste from laboratories (service) as well as the first to create 100% recycled laboratory consumables (product). Working with public and private labs, we are driving the circular economy of lab plastics to reduce the 5.5m tonnes of lab waste annually. A few highlights of ourprogress to date: • Proven impact - saving 90% of CO2 emissions & 93% energy compared to current alternatives: incineration and autoclave (LCA available upon request).• Technological validation creating the world's first 100% circular lab consumables including petri dishes, test tubes and more.• Secured commercial contracts with the NHS, several private companies and also universities. We are raising £1.5m to scale our patent pending technology to serve our growing demand after over 150+ organic expressions of interests following our feature in BBC news. The funding will establish the first automated decontamination system of our network, recycling over 350 tonnes annually, saving over 1000+ tonnes of carbon. | $1.3M / Seed / Jan 19, 2026 | |
EnsiliTech
|
EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials. | $6.1M / Seed / Aug 28, 2025 | |
Lutra Health
|
Lutra Health mission is to connect eyecare providers and equip them with the tools they need to deliver care more efficiently and effectively. | $471K / Seed / Jun 20, 2025 | |
Light Trace Photonics
|
Light Trace Photonics utilizes the power of integrated photonics to provide a variety of products and services that aid in educational and innovative endeavors. | $759.3K / Seed / Nov 20, 2024 | |
|
iFast Diagnostics
|
iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance. | $6.5M / Seed / Nov 04, 2024 | |
|
iFast Diagnostics
|
iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance. | $6.5M / Seed / Nov 04, 2024 | |
Kelpi
|
Kelpi is a sustainable biotech start-up bio-refining seaweed to make bioplastic packaging that is marine-safe and home-compostable. | $5.5M / Seed / May 30, 2024 | |
| See all 27 investments → | |||
Co-Investors
APEX Ventures
7 deals together
Meridian Health Ventures
6 deals together
Emerging Longevity Ventures
5 deals together
Empirical Ventures
5 deals together
Lifespan Vision Ventures
5 deals together
R42 Group
5 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does QantX invest in?
QantX invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Angel stage. Most of the 27 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is QantX's check size?
QantX typically joins rounds of $471k–$6.5M at Seed, $382k–$1.3M at Angel and $764k–$1.1M at Pre-Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds QantX participates in.
How do I contact QantX?
Public channels for QantX include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at QantX?
The team at QantX includes Richard Haycock (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
